91̽

University 91̽
  2. About
  3. Find staff
  4. Roger Olofsson Bagge

Roger Olofsson Bagge

Professor/ Chief Physician

Department of Surgery
Mail
roger.olofsson.bagge@gu.se
Visiting address
Blå stråket 5, vån 3 SU/Sahlgrenska
41345 Göteborg
Postal address
Sahlgrenska Universitetssjukhuset
41345 Göteborg

About Roger Olofsson Bagge

(1:30)

Roger Olofsson Bagge, MD, PhD, is a Professor of Cancer Surgery at the University 91̽ and a Senior Consultant Surgeon at Sahlgrenska University Hospital, where he also leads a translational research group focused on melanoma and breast cancer. He holds a key position at the Sahlgrenska Comprehensive Cancer Center and is affiliated with the Wallenberg Centre for Molecular and Translational Medicine. His clinical and academic career is rooted in surgical oncology with a particular emphasis on regional therapies for melanoma and translational models to support clinical innovation.

Olofsson Bagge has an extensive publication record, with over 150 peer-reviewed scientific articles with impactful work spanning isolated limb and hepatic perfusion, immunotherapy integration, and national registry-based studies. He is frequently involved in international collaborative studies and guideline development, with multiple recent publications in British Journal of Surgery, JAMA Dermatology, Lancet Oncology, New England Journal of Medicine, and Nature Communications.He has secured substantial external research funding, including Swedish Research Council, Swedish Cancer Society, Sjöberg Foundation, Wallenberg Foundation, Swedish Society for Medical Research and American Association for Cancer Research. These grants support both clinical trials and preclinical models, including research within the fields of extracellular vesicles, patient-derived xenograft (PDX) systems and immunological profiling of melanoma.

Olofsson Bagge serves as principal investigator for several national and international investigator-initiated trials, such as the SCANDIUM I, II and III trials evaluating isolated hepatic perfusion for uveal melanoma liver metastases and the NivoILP study on immune checkpoint blockade combined with regional therapy for in-transit melanoma. He has also played an important academic role in large breast cancer trials including SENOMAC and PhysSURG-B, contributing to shifts in surgical standards.He is actively engaged in doctoral supervision and academic mentorship, currently serving as main or co-supervisor for over ten PhD students. He manages a patient-derived tumor biobank and coordinates research collaborations across oncology, surgery, extracellular vesicles and immunology. Through this platform, he has built a strong infrastructure for clinical-translational research that bridges experimental modeling with real-world impact in cancer care.

Pressrelease 230321 Effective treatment in rare but deadly form of cancer

Major research funding

  • Swedish Research Council (Vetenskapsrådet)
  • American Association for Cancer Research (AACR)
  • Swedish Cancer Society (Cancerfonden)
  • Wallenberg Foundation
  • Region Västra Götaland
  • Assar Gabrielsson foundation
  • Gothenburg Medical Association
  • Swedish state (ALF-agreement)
  • Gothenburg research council

Received grants and prizes - 2021 and forwards